

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Gryphon Therapeutics, Inc.	12/21/2005
RECEIVING PARTY DATA	
Name:	Amylin Pharmaceuticals, Inc.
Street Address:	9360 Towne Centre Drive
City:	San Diego
State/Country:	CALIFORNIA
Postal Code:	92121
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	60229295
Application Number:	10332454
CORRESPONDENCE DATA	
Fax Number:	(858)552-1936
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(858) 552-2200
Email:	ahalverson@amylin.com
Correspondent Name:	Molly A Holman, Ph.D.
Address Line 1:	Amylin Pharmaceuticals, Inc.
Address Line 2:	9360 Towne Centre Drive
Address Line 4:	San Diego, CALIFORNIA 92121
ATTORNEY DOCKET NUMBER:	0936-GY
NAME OF SUBMITTER:	Amanda J. Halverson
Total Attachments: 3 source=036 Assignment#page1.tif source=036 Assignment#page2.tif	

CH 60229295 \$80.00

500072289

PATENT
REEL: 017038 FRAME: 0657

ASSIGNMENT

WHEREAS, **GRYPHON THERAPEUTICS, INC.**, of 35473 Dumbarton Ct., Newark, CA 94560 (c/o Rose Ryan), formerly of South San Francisco, California, United States of America, a Corporation of the State of California, the undersigned Assignor, hereby states it is the owner of each of the patent applications and patents identified herein and on the attached Exhibit 1 and inventions disclosed therein by virtue of obligations to assign to it by the original inventors or by virtue of Assignments to it by either the original inventors or by the previous owner Gryphon Sciences, of South San Francisco, California, United States of America;

WHEREAS, **AMYLIN PHARMACEUTICALS, INC.**, of San Diego, California, United States of America, a Corporation of the State of Delaware, is desirous of acquiring the entire right, title and interest in and to said invention or inventions and any and all patents to be obtained therefor;

NOW, THEREFORE, FOR GOOD AND VALUABLE CONSIDERATION, the receipt of which is hereby acknowledged, **GRYPHON THERAPEUTICS, INC.** does hereby sell, assign and transfer to **AMYLIN PHARMACEUTICALS, INC.**, ("Assignee") its successors and assigns, the entire right, title and interest in and to said application(s), patent(s) and/or invention(s), in any form or embodiment, whether or not listed in Exhibit 1; and in and to any and all applications filed in any country based thereon, whether or not listed in Exhibit 1, including the right to file applications in countries other than the country of priority filing under the provisions of any international convention; also the entire right, title and interest in and to any and all patents, including reissues and extensions thereof, obtained in any country upon said inventions, whether or not listed in Exhibit 1; and to any and all continuing applications, including divisional, continuation and continuation-in-part applications and substitute applications; to all prior applications disclosing said inventions to which said present application(s) or patents(s) claim priority, including any not listed in Exhibit 1; and to any other applications claiming the benefit of said prior applications, including any not listed in Exhibit 1.

Notwithstanding the foregoing paragraph, said application(s), patent(s), and/or invention(s) assigned and transferred hereby shall include only Assignor's rights to applications, patents and/or inventions relating directly to CPS Technology as defined in the Purchase Agreement between **GRYPHON THERAPEUTICS, INC.**, and **AMYLIN PHARMACEUTICALS, INC.** dated November 28, 2005 (the "Purchase Agreement"), and shall not include Assignor's rights to applications, patents and/or inventions relating to patent families that are not listed in Schedule 1.1(a) to the Purchase Agreement.

GRYPHON THERAPEUTICS, INC. hereby authorizes and requests the issuing authority to issue any and all patents on said application or applications to **AMYLIN**

AND for the same consideration, **GRYPHON THERAPEUTICS, INC.** hereby covenants and agrees to and with **AMYLIN PHARMACEUTICALS, INC.**, its successors, legal representatives and assigns, that **GRYPHON THERAPEUTICS, INC.** will, and, hereby

grants to the **Assignee** the right to enforce the original inventors' obligations to assign their rights to **GRYPHON THERAPEUTICS, INC.** such that consistent with their obligations to assign to **GRYPHON THERAPEUTICS, INC.**, the original inventors will, whenever counsel of the said Assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent, or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said Assignee, its successors, legal representatives and assigns, but at the cost and expense of said Assignee, its successors, legal representatives and assigns.

IN TESTIMONY WHEREOF, **GRYPHON THERAPEUTICS, INC.** has hereto set its hands on the dates set after its signature.

Signature: *F. Blobel* Date: *12/21/05*

Friedhelm Blobel


CEO and President

Gryphon Therapeutics, Inc.

State of California)
)
County of *San Mateo* ss.

On this *21* day of *December*, 2005, before me, *Sylvia Rogers*
Notary Public, personally appeared *Friedhelm Blobel*, personally known
to me or proved to me on the basis of satisfactory evidence to be the person who executed
the foregoing instrument and acknowledged that he/~~she~~ executed the same as his/~~her~~ free
act and deed; in testimony whereof I have hereto set my hand and official seal on the day
last above written.

Sylvia Rogers



PATENT

REEL: 017038 FRAME: 0660

Assignment of Applications and Patents to **AMYLIN PHARMACEUTICALS, INC**
Patent Family 036

Page 3 of 3

Exhibit 1

Application or Patent No. (US and foreign)	Filing Date or Issuance Date	Country	Gryphon Docket Number	Issue Date	Patent	USPTO Recorded Prior Assignment to Gryphon Sciences (Reel/Frame)	USPTO Recorded Prior Assignment to Gryphon Therapeutics (Reel/Frame)
60/229,295	9/1/2000	UNITED STATES	036/00US				Reel: 013996 Frame: 0401
2001293231	8/30/2001	AUSTRALIA	036/01AU				
2,412,424	8/30/2001	CANADA	036/01CA				
01815056.X	8/30/2001	CHINA	036/01CN				
01973676.8	8/30/2001	EUROPEAN PATENT	036/01EP				
153878	8/30/2001	ISRAEL	036/01IL				
2002-523931	8/30/2001	JAPAN	036/01JP				
2003-7000817	8/30/2001	SOUTH KOREA	036/01KR				
PA/a/2003/001449	8/30/2001	MEXICO	036/01MX				
524222	8/30/2001	NEW ZEALAND	036/01NZ				
10/332,454	8/30/2001	UNITED STATES	036/01US				Reel: 013996 Frame: 0401
PCT/US01/41938	8/30/2001	WIPO	036/01WO				Reel: 013996 Frame: 0401

PATENT

RECORDED: 01/19/2006

REEL: 017038 FRAME: 0661